Rigel Pharmaceuticals Stock Analysis

Rigel Stock Analysis Notes

About 91.0% of the company shares are owned by institutional investors. The company recorded earning per share (EPS) of 6.34. Rigel Pharmaceuticals had not issued any dividends in recent years. The entity had 1:10 split on the 27th of June 2024. Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California. Rigel Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 165 people. To find out more about Rigel Pharmaceuticals contact Raul Rodriguez at 650 624 1100 or learn more at https://www.rigel.com.

Rigel Pharmaceuticals Investment Alerts

Rigel Largest EPS Surprises

View All Earnings Estimates

Rigel Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Rigel Pharmaceuticals Thematic Classifications

Rigel Stock Institutional Investors

Note, although Rigel Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Rigel Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 665.07 M.

Rigel Profitablity

The company has Profit Margin (PM) of 0.4 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.41 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.41.

Management Efficiency

Rigel Pharmaceuticals has return on total asset (ROA) of 0.3893 % which means that it generated a profit of $0.3893 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 2.2006 %, meaning that it created $2.2006 on every $100 dollars invested by stockholders. Rigel Pharmaceuticals' management efficiency ratios could be used to measure how well Rigel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to 0.12 this year. Return On Capital Employed is expected to rise to 0.23 this year. At this time, Rigel Pharmaceuticals' Fixed Asset Turnover is quite stable compared to the past year. Return On Assets is expected to rise to 0.10 this year, although the value of Non Currrent Assets Other will most likely fall to about 1.2 M.

Technical Drivers

As of the 20th of February, Rigel Pharmaceuticals holds the Coefficient Of Variation of (8,741), risk adjusted performance of (0.0007), and Variance of 16.48. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rigel Pharmaceuticals, as well as the relationship between them. Please check Rigel Pharmaceuticals standard deviation and value at risk to decide if Rigel Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 36.64 per share. Given that Rigel Pharmaceuticals has information ratio of (0.03), we recommend you to check out Rigel Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.

Rigel Pharmaceuticals Price Movement Analysis

Rigel Pharmaceuticals Insider Trading Activities

Rigel Pharmaceuticals Outstanding Bonds

Rigel Pharmaceuticals Predictive Daily Indicators

Rigel Pharmaceuticals Corporate Filings

Rigel Pharmaceuticals Forecast Models

Rigel Pharmaceuticals' time-series forecasting models are one of many Rigel Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Rigel Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Rigel Pharmaceuticals Bond Ratings

Rigel Pharmaceuticals financial ratings play a critical role in determining how much Rigel Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Rigel Pharmaceuticals' borrowing costs.

Rigel Pharmaceuticals Debt to Cash Allocation

Rigel Pharmaceuticals currently holds 59.97 M in liabilities. Rigel Pharmaceuticals has a current ratio of 2.29, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Rigel Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Rigel Pharmaceuticals Total Assets Over Time

Rigel Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Rigel Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Rigel Pharmaceuticals Debt Ratio

35.0

It seems about 65% of Rigel Pharmaceuticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Rigel Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Rigel Pharmaceuticals, which in turn will lower the firm's financial flexibility.

Rigel Pharmaceuticals Corporate Bonds Issued

Rigel Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Rigel Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Rigel shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Rigel Pharmaceuticals. By using and applying Rigel Stock analysis, traders can create a robust methodology for identifying Rigel entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Rigel analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Rigel analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Rigel Pharmaceuticals stock analysis indicators help investors evaluate how Rigel Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Rigel Pharmaceuticals shares will generate the highest return on investment. By understating and applying Rigel Pharmaceuticals stock analysis, traders can identify Rigel Pharmaceuticals position entry and exit signals to maximize returns.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Investors evaluate Rigel Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Rigel Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Rigel Pharmaceuticals' market price to deviate significantly from intrinsic value.

It's important to distinguish between Rigel Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rigel Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Rigel Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.